Aetna modified CPB 0717 covering volatile organic compound (VOC) analysis, effective November 27, 2025. Here's what billing teams need to know.
Aetna, a CVS Health company, updated Clinical Policy Bulletin 0717 to classify VOC analysis as experimental, investigational, or unproven across more than 30 clinical indications — including cancer detection, lung disease diagnosis, and COVID-19 screening. The CPB 0717 Aetna system update covers a broad ICD-10 code set spanning 402 diagnosis codes across tuberculosis (A15.0–A19.9), malignant neoplasms (C00.0–C96.9), and dozens of other condition ranges. If your team is billing VOC analysis for any Aetna member, expect a claim denial.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Analysis of Volatile Organic Compounds — CPB 0717 |
| Policy Code | CPB 0717 |
| Change Type | Modified |
| Effective Date | November 27, 2025 |
| Impact Level | High |
| Specialties Affected | Pulmonology, Oncology, Infectious Disease, Gastroenterology, Neurology, Nephrology, Transplant Medicine, Sleep Medicine, Neonatology |
| Key Action | Audit any claims billed with VOC analysis for Aetna members and remove from charge capture immediately |
Aetna Volatile Organic Compound Analysis Coverage Criteria and Medical Necessity Requirements 2025
The Aetna volatile organic compound coverage policy is straightforward in one direction: there is no covered indication. Aetna does not recognize VOC analysis as meeting medical necessity for any clinical use case. This is a blanket experimental designation, not a narrow carve-out.
VOC analysis involves measuring chemical compounds exhaled in breath, excreted in urine, or emitted from skin or wound tissue. Proponents argue these biomarkers can detect cancer, infections, and metabolic conditions non-invasively. Aetna's position is that the clinical evidence does not support routine use. CPB 0717 states the clinical effectiveness of this technique has not been established.
Prior authorization won't save you here. This isn't a prior auth issue — it's a coverage issue. Even if you obtained prior authorization for VOC analysis, Aetna's experimental classification means reimbursement is off the table. The coverage policy gives no pathway to approval.
The real issue is that VOC analysis is an emerging field. Research is active. But "active research" and "covered by insurance" are different things. Aetna has drawn a hard line, and that line holds as of November 27, 2025.
Aetna VOC Analysis Exclusions and Non-Covered Indications
This is the core of CPB 0717, and the list is long. Aetna classifies every one of the following as experimental, investigational, or unproven. None qualifies as a covered service under this Aetna volatile organic compound coverage policy.
Oncology indications — all denied:
| # | Excluded Procedure |
|---|---|
| 1 | Bladder cancer detection |
| 2 | Breast cancer detection |
| 3 | Colorectal cancer detection |
| 4 | Esophagogastric cancer detection |
| 5 | Gallbladder cancer detection |
| 6 | Gastric cancer detection |
| 7 | Hepatobiliary cancer detection |
| 8 | Leukemia and lymphoma detection |
| 9 | Lung cancer and cancer of the pleura detection |
| 10 | Pancreatic cancer detection |
| 11 | Renal cancer detection |
| 12 | Differential diagnosis of breast diseases (including breast cancer, cyclomastopathy, and mammary gland fibroma) |
Pulmonology and respiratory indications — all denied:
| # | Excluded Procedure |
|---|---|
| 1 | Diagnosis of lung disease, including asthma |
| 2 | Prediction of asthma exacerbations |
| 3 | Prediction of bronchopulmonary dysplasia in preterm infants |
| 4 | Detection of bronchiolitis obliterans syndrome in lung transplant recipients |
| 5 | Use as biomarkers of chronic obstructive pulmonary disease |
| 6 | Diagnosis of pneumonia |
| 7 | Diagnosis and monitoring of pleural mesothelioma |
| 8 | Diagnosis and monitoring of sarcoidosis |
Infectious disease indications — all denied:
| # | Excluded Procedure |
|---|---|
| 1 | Detection of bacteriuria |
| 2 | Diagnosis of infection (general) |
| 3 | Diagnosis of tuberculosis |
| 4 | Diagnosis of oral candidiasis |
| 5 | Screening for COVID-19 |
Gastroenterology and hepatology indications — all denied:
| # | Excluded Procedure |
|---|---|
| 1 | Diagnosis of inflammatory bowel disease |
| 2 | Diagnosis of celiac disease |
| 3 | Diagnosis of non-alcoholic fatty liver disease |
| 4 | Diagnosis of alcoholic hepatitis |
Nephrology and other metabolic indications — all denied:
| # | Excluded Procedure |
|---|---|
| 1 | Diagnosis of idiopathic membranous nephropathy |
| 2 | Use as markers for monitoring hemodialysis efficiency |
Neurology and developmental indications — all denied:
| # | Excluded Procedure |
|---|---|
| 1 | Diagnosis of Parkinson's disease |
| 2 | Diagnosis of neuromuscular disease, including amyotrophic lateral sclerosis |
| 3 | Diagnosis of autism spectrum disorders |
| 4 | Diagnosis of juvenile idiopathic arthritis |
Other indications — all denied:
| # | Excluded Procedure |
|---|---|
| 1 | Diagnosis of obstructive sleep apnea |
| 2 | Diagnosis of non-healing surgical wounds |
| 3 | Prediction of development of childhood obesity |
| 4 | Prediction of development of necrotizing enterocolitis |
The phrase "not an all-inclusive list" appears twice in the policy. Aetna is signaling that this list doesn't cap the exclusions. If a new application of VOC analysis comes up, expect the same denial.
Coverage Indications at a Glance
| Indication | Coverage Status | Relevant ICD-10 Codes | Notes |
|---|---|---|---|
| Cancer detection (bladder, breast, colorectal, gastric, hepatobiliary, leukemia/lymphoma, lung, pancreatic, renal, gallbladder, esophagogastric) | Experimental / Not Covered | C00.0–C96.9; D00.1, D00.2; D05.0–D05.99 | No prior auth pathway; blanket exclusion |
| Pleural mesothelioma diagnosis and monitoring | Experimental / Not Covered | C45.x range within C00.0–C96.9 | Includes ongoing monitoring, not just initial diagnosis |
| Sarcoidosis diagnosis and monitoring | Experimental / Not Covered | Within covered ICD-10 range | Both diagnosis and monitoring excluded |
| Bronchiolitis obliterans syndrome (lung transplant recipients) | Experimental / Not Covered | Within applicable ICD-10 range | Transplant post-op monitoring not covered via VOC |
| Lung disease diagnosis (including asthma) | Experimental / Not Covered | Within applicable ICD-10 range | Asthma exacerbation prediction also excluded |
| COPD biomarker use | Experimental / Not Covered | Within applicable ICD-10 range | Biomarker monitoring not covered |
| Tuberculosis diagnosis | Experimental / Not Covered | A15.0–A19.9 | Full tuberculosis ICD-10 range listed in policy |
| Bacteriuria detection | Experimental / Not Covered | Within applicable ICD-10 range | No coverage for urinary infection screening via VOC |
| COVID-19 screening | Experimental / Not Covered | Within applicable ICD-10 range | Explicitly listed as excluded |
| Inflammatory bowel disease diagnosis | Experimental / Not Covered | Within applicable ICD-10 range | |
| Celiac disease diagnosis | Experimental / Not Covered | Within applicable ICD-10 range | |
| Non-alcoholic fatty liver disease diagnosis | Experimental / Not Covered | Within applicable ICD-10 range | |
| Alcoholic hepatitis diagnosis | Experimental / Not Covered | Within applicable ICD-10 range | |
| Idiopathic membranous nephropathy diagnosis | Experimental / Not Covered | Within applicable ICD-10 range | |
| Hemodialysis efficiency monitoring | Experimental / Not Covered | Within applicable ICD-10 range | |
| Parkinson's disease diagnosis | Experimental / Not Covered | Within applicable ICD-10 range | |
| ALS and other neuromuscular disease diagnosis | Experimental / Not Covered | Within applicable ICD-10 range | |
| Autism spectrum disorder diagnosis | Experimental / Not Covered | Within applicable ICD-10 range | |
| Juvenile idiopathic arthritis diagnosis | Experimental / Not Covered | Within applicable ICD-10 range | |
| Obstructive sleep apnea diagnosis | Experimental / Not Covered | Within applicable ICD-10 range | |
| Oral candidiasis diagnosis | Experimental / Not Covered | B37.0 | Candidal stomatitis explicitly listed |
| Non-healing surgical wound diagnosis | Experimental / Not Covered | Within applicable ICD-10 range | |
| Childhood obesity prediction | Experimental / Not Covered | Within applicable ICD-10 range | |
| Necrotizing enterocolitis prediction | Experimental / Not Covered | Within applicable ICD-10 range | |
| Bronchopulmonary dysplasia prediction (preterm) | Experimental / Not Covered | Within applicable ICD-10 range | |
| Breast disease differential diagnosis | Experimental / Not Covered | D05.0–D05.99; within C00.0–C96.9 | Includes cyclomastopathy and mammary gland fibroma |
| Pneumonia diagnosis | Experimental / Not Covered | Within applicable ICD-10 range |
Aetna Volatile Organic Compound Billing Guidelines and Action Items 2025
The effective date is November 27, 2025. If your team has already submitted VOC analysis claims for Aetna members after that date, start there.
| # | Action Item |
|---|---|
| 1 | Audit claims submitted after November 27, 2025. Pull any claim that includes VOC analysis for Aetna members. Flag them for review before they generate a denial and a secondary work queue. |
| 2 | Remove VOC analysis from your charge capture for Aetna patients. This isn't a coding adjustment — it's a service coverage issue. No diagnosis code combination makes this billable to Aetna. Volatile organic compound billing to Aetna should stop. |
| 3 | Check your ABN process if you offer VOC analysis outside insurance. If your practice performs VOC testing as a self-pay or cash-pay service, use an Advance Beneficiary Notice of Noncoverage equivalent for Aetna members. Make sure patients understand Aetna will not cover it before the test is ordered. |
| 4 | Train your clinical and scheduling staff. Physicians ordering VOC analysis may not know about CPB 0717. Talk to your medical director. Put a flag in your EHR order set for Aetna members so the ordering provider sees the non-coverage status before the test is run. |
| 5 | Watch for experimental technology claims bundled inside larger encounters. VOC analysis sometimes appears as part of a broader research protocol or diagnostic panel. If any component maps to experimental VOC testing, Aetna will deny it. Scrub your encounter forms for bundled experimental services. |
| 6 | If you're in a research or academic setting, loop in your compliance officer. Some institutions bill VOC analysis under research protocols. This coverage policy doesn't change the experimental nature of the service — but your billing guidelines need to reflect that Aetna won't pay. Your compliance officer should confirm how this interacts with any research billing arrangements. |
There is no appeals pathway that will overturn an experimental designation at the individual claim level. You can appeal on a case-by-case basis, but you are fighting the underlying policy. That's a different process — and a slow one. Don't plan your revenue around it.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Volatile Organic Compound Analysis Under CPB 0717
CPB 0717 does not list specific CPT or HCPCS procedure codes. The policy classifies VOC analysis at the service level, not the code level. This means any procedure code used to bill VOC analysis to Aetna falls under this experimental designation.
This matters for volatile organic compound billing because coders sometimes look for a code-level denial trigger and don't find one — then assume the service is billable. It isn't. The denial comes from the service category, not from a specific CPT being flagged.
Key ICD-10-CM Diagnosis Codes Referenced in CPB 0717
The policy attaches 402 ICD-10-CM codes. Below are the primary code ranges and specific codes explicitly listed.
| Code / Range | Description |
|---|---|
| A15.0 – A19.9 | Tuberculosis |
| B37.0 | Candidal stomatitis (oral candidiasis) |
| C00.0 – C96.9 | Malignant neoplasms |
| D00.1 | Carcinoma in situ of esophagus |
| D00.2 | Carcinoma in situ of stomach |
| D05.0 – D05.99 | Carcinoma in situ of breast (all subcategories) |
The D05.x range is granular in the policy — it lists every subcategory from D05.0 through D05.99. All are included in the non-covered designation.
The full 402-code list spans tuberculosis through malignant neoplasms and carcinoma in situ codes. The breadth of the ICD-10 list reflects how many clinical use cases Aetna is closing off. If you're trying to confirm whether a specific diagnosis code falls under this policy, check the full CPB 0717 document at Aetna's clinical policy library.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.